Lapam Capital, headquartered in Beijing, is a leading biopharmaceutical venture capital firm in China. It currently manages five RMB-denominated funds and one USD-denominated fund, with total assets under management (AUM) exceeding RMB 10 billion. It is the only biopharmaceutical investment institution in China that has received capital support from both the National Social Security Fund (NSSF) and the National Small and Medium Enterprises Development Fund (SME Fund).  

Lapam Capital focuses on innovative drugs and innovative medical devices, primarily investing in early- to mid-stage projects. To date, the firm has invested in over 200 companies, including more than 160 innovative drug companies and over 30 innovative medical device companies. Its portfolio includes notable enterprises such as Beta Pharma (SZ.300558), RemeGen (SH.688331; HK.09995), EyeBio (SH.688050), Asieris Pharmaceuticals (SH.688176), Kewei Science (SH.688687), ImmuneOnco Biopharma (HK.01541), Continy Pharmaceutical (NASDAQ: GYRE), Huahao Tianrun (HK.02563), Lide Biotech (HK.09887), BinHui Biotechnology, Wuhe Boao, Benda Gene, Weizhi Zhuo, and Xinhanglu, among many other standout projects.  

Multiple partners within the Lonpac team possess over 20 years of international and domestic biopharmaceutical industry experience in research, development, and management. The firm is dedicated to providing systematic, comprehensive strategic value-added support to its portfolio companies.